Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul M Sondel

Showing results (1-10 of 152) with videos related to

Pageof 16
Sort By:
Current Opinion in Immunology|April 10, 2016
Immunocytokines for cancer treatment: past, present and futureDario Neri, Paul M Sondel
Journal of Pediatric Hematology/Oncology|March 22, 2019
Advances in Anti-GD2 Immunotherapy for Treatment of High-risk NeuroblastomaJulie Voeller, Paul M Sondel
Seminars in Oncology|August 31, 2015
Enhancing Cancer Immunotherapy Via Activation of Innate ImmunityJacob L Goldberg, Paul M Sondel
Journal of Biomedicine & Biotechnology|June 11, 2011
Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicityKory L Alderson, Paul M Sondel
Antibodies (Basel, Switzerland)|March 18, 2014
Current and Potential Uses of Immunocytokines as Cancer ImmunotherapyPaul M Sondel, Stephen D Gillies
Drugs of the Future|November 2, 2010
Anti-GD2 Strategy in the Treatment of NeuroblastomaRichard K Yang, Paul M Sondel
Expert Reviews in Molecular Medicine|December 18, 2007
Antibody-based immunotherapy in high-risk neuroblastomaErik Johnson, Shannon M Dean, Paul M Sondel
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2022
Immunotherapy of Neuroblastoma: Facts and HopesJohn Anderson, Robbie G Majzner, Paul M Sondel
Immunotherapy|August 4, 2016
Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapyZulmarie Perez Horta, Jacob L Goldberg, Paul M Sondel
International Reviews of Immunology|July 19, 2012
T-cell-independent antitumor effects of CD40 ligationAlexander L Rakhmilevich, Kory L Alderson, Paul M Sondel
Pageof 16

Showing results (1-10 of 152) with videos related to

Sort By:
Pageof 16
Current Opinion in Immunology|April 10, 2016
Immunocytokines for cancer treatment: past, present and futureDario Neri, Paul M Sondel
Journal of Pediatric Hematology/Oncology|March 22, 2019
Advances in Anti-GD2 Immunotherapy for Treatment of High-risk NeuroblastomaJulie Voeller, Paul M Sondel
Seminars in Oncology|August 31, 2015
Enhancing Cancer Immunotherapy Via Activation of Innate ImmunityJacob L Goldberg, Paul M Sondel
Journal of Biomedicine & Biotechnology|June 11, 2011
Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicityKory L Alderson, Paul M Sondel
Antibodies (Basel, Switzerland)|March 18, 2014
Current and Potential Uses of Immunocytokines as Cancer ImmunotherapyPaul M Sondel, Stephen D Gillies
Drugs of the Future|November 2, 2010
Anti-GD2 Strategy in the Treatment of NeuroblastomaRichard K Yang, Paul M Sondel
Expert Reviews in Molecular Medicine|December 18, 2007
Antibody-based immunotherapy in high-risk neuroblastomaErik Johnson, Shannon M Dean, Paul M Sondel
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2022
Immunotherapy of Neuroblastoma: Facts and HopesJohn Anderson, Robbie G Majzner, Paul M Sondel
Immunotherapy|August 4, 2016
Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapyZulmarie Perez Horta, Jacob L Goldberg, Paul M Sondel
International Reviews of Immunology|July 19, 2012
T-cell-independent antitumor effects of CD40 ligationAlexander L Rakhmilevich, Kory L Alderson, Paul M Sondel
Pageof 16